NCT02410031View on ClinicalTrials.gov

Risk Minimisation Study for Diane-35 and Its Generics

CompletedOBSERVATIONAL
Enrollment

759

Participants

Timeline

Start Date

June 26, 2015

Primary Completion Date

March 4, 2016

Study Completion Date

March 4, 2016

Conditions
Acne Vulgaris
Interventions
DRUG

Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)

Cyproterone acetate 2mg/ethinylestradiol 35 μg

Trial Locations (5)

Unknown

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

RTI Health Solutions

OTHER

lead

Bayer

INDUSTRY